title: The triple threat of HIV-1 protease inhibitors.
abstract: Newly released human immunodeficiency virus type 1 (HIV-1) particles obligatorily undergo a maturation process to become infectious. The HIV-1 protease (PR) initiates this step, catalyzing the cleavage of the Gag and Gag-Pro-Pol structural polyproteins. Proper organization of the mature virus core requires that cleavage of these polyprotein substrates proceeds in a highly regulated, specific series of events. The vital role the HIV-1 PR plays in the viral life cycle has made it an extremely attractive target for inhibition and has accordingly fostered the development of a number of highly potent substrate-analog inhibitors. Though the PR inhibitors (PIs) inhibit only the HIV-1 PR, their effects manifest at multiple different stages in the life cycle due to the critical importance of the PR in preparing the virus for these subsequent events. Effectively, PIs masquerade as entry inhibitors, reverse transcription inhibitors, and potentially even inhibitors of post-reverse transcription steps. In this chapter, we review the triple threat of PIs: the intermolecular cooperativity in the form of a cooperative dose-response for inhibition in which the apparent potency increases with increasing inhibition; the pleiotropic effects of HIV-1 PR inhibition on entry, reverse transcription, and post-reverse transcription steps; and their potency as transition state analogs that have the potential for further improvement that could lead to an inability of the virus to evolve resistance in the context of single drug therapy.
authors.affiliation: Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, 27599, USA.
authors.forename: Marc
authors.initials: M
authors.lastname: Potempa
authors.forename: Sook-Kyung
authors.initials: SK
authors.lastname: Lee
authors.forename: Richard
authors.initials: R
authors.lastname: Wolfenden
authors.forename: Ronald
authors.initials: R
authors.lastname: Swanstrom
mesh_terms: D016333:HIV Protease / Q000502:physiology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D048348:Reverse Transcription / Q000187:drug effects; D053586:Virus Internalization / Q000187:drug effects
chemical_list: D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1